![]() |
市場調查報告書
商品編碼
1423587
藥物釋放型球囊導管的全球市場預測(-2030):按產品、藥物、材料、最終用戶和地區進行分析Drug-eluting Balloon Catheters Market Forecasts to 2030 - Global Analysis By Product (Coronary Artery Balloon Catheters and Peripheral Vascular Balloon Catheters), Drug, Material, End User and By Geography |
2023年全球藥物釋放型球囊導管市場規模為6.51億美元,預計預測期內複合年成長率為10.9%,到2030年達到13.432億美元。稱為藥物藥物釋放型球囊導管 (DEB) 的醫療設備在介入性心臟病學中用於治療周邊動脈疾病(PAD) 和冠狀動脈疾病 (CAD)。
這些導管的目的是將藥物直接注射到受損的血管壁中,以阻止血管再阻塞,即血管成形術治療後的血管收縮。由於藥物塗層和導管技術的發展,以及專注於改善患者治療效果和安全性的持續臨床研究,藥物釋放型球囊導管市場正在不斷變化。
根據美國心臟協會 2021 年的報告,周邊動脈疾病(PAD) 影響全球 2 億多人,並與高死亡率和發病率有關。此外,易患心血管疾病的老年人口的增加和醫療保健支出的增加預計將推動市場成長。
心血管疾病的盛行率
隨著心血管疾病的發生率增加,需要介入治療來控制動脈阻塞的患者數量也在增加。對於這些患者來說,藥物釋放型球囊導管是一種有效的治療選擇,可能會增加使用這些設備的治療數量。此外,醫療保健費用也受到心血管疾病經濟負擔的影響,包括後續觀察、住院和治療。因此,如果藥物釋放型球囊導管被證明可以透過血管再阻塞和再手術來節省長期醫療成本,那麼它們將成為創新和成功治療方法的典範,從而推動市場成長,並有可能廣泛應用。
根據病變類型,臨床證據有限
支持使用藥物釋放型球囊導管的臨床資料有限,可能會限制醫療保健負責人針對特定病變類型可用的有效治療方法的數量。這種限制可能會阻止患有某些動脈病變的患者接受最佳治療。這些導管被認為是潛在的良好替代品,特別是在缺乏可靠資料來支持其使用的情況下。雖然這些系統在某些情況下可能是有益的,但它們可能會導致選擇更多基於證據的治療方法,從而錯失改善患者護理的機會,從而推動市場成長。
擴大臨床證據
藥物釋放型球囊導管安全有效,具有良好的長期效果。此類資料支援其使用並鼓勵醫療保健專業人員使用它。越來越多的臨床資料證明藥物釋放型球囊導管的優越性可能會對醫療保健付款人的報銷決策產生積極影響。事實證明,更好的患者治療效果可能會帶來更有利的報銷規則,從而增加市場進入和設備利用率。
成本和報銷挑戰
患者使用藥物釋放型球囊導管可能會因支付問題而受到阻礙,特別是在保險範圍和報銷法律不利的地區和衛生系統中。這些限制可能會阻止患者平等地獲得尖端治療方法,並可能影響預後,這取決於保險狀況和地理位置。保險報銷困難或缺乏保險覆蓋範圍可能會阻礙藥物釋放型球囊導管市場的滲透和接受度。
COVID-19 的影響
在大流行最嚴重的時候,許多醫院和醫療機構在獲取資源時優先考慮 COVID-19 患者。因此,選擇性手術,包括藥物釋放型球囊血管成形術等非緊急心臟介入措施,不得不延後或取消。因此,市場上使用這些設備進行的手術數量有所減少。隨著疫苗接種率的提高和衛生系統適應這一流行病,選擇性手術和非緊急干預措施已穩步恢復。一些醫療機構的重新開放導致對心血管治療的需求增加,特別是那些需要球囊導管釋放藥物的治療。
冠狀動脈球囊導管領域預計將成為預測期內最大的市場
冠狀動脈球囊導管可以疏通或拓寬冠狀動脈,以補充心肌的血液供應,因此該領域有望迎來良好的成長。特別是,藥物釋放型球囊導管是一種將藥物直接輸送到動脈阻塞部位以避免血管再阻塞的導管。此外,對微創手術的需求、心血管疾病盛行率的上升以及藥物釋放型球囊比傳統血管成形術更有效地降低血管再阻塞率這一事實正在推動市場成長。
紫杉醇細分市場預計在預測期內複合年成長率最高
由於擔心其安全性,特別是其與周邊動脈疾病(PAD) 患者的長期影響和死亡率增加的關係,紫杉醇在藥物釋放型球囊(DEB) 導管中的使用受到了廣泛關注。研究正在進行中。此外,由於圍繞這些設備的安全問題,藥物釋放型球囊導管和其他紫杉醇塗層產品的市場動態正在改變。因此,關於加強監測、改變臨床程序、患者選擇和長期安全性監測的討論越來越多。
由於多個領先製造商的存在、技術先進的新技術設備的引進、有利的報銷政策等是北美市場佔有率的主要因素,預計北美地區將在預測期內實現成長。爭取最大的市場佔有率。例如,美國心臟協會估計,美國每年進行超過 50 萬例經皮經皮成形術,包括經皮腔內冠狀動脈介入治療。
由於醫療保健成本上升和心血管疾病的流行,預計亞太地區在預測期內將呈現最高的複合年成長率。據Biomedcentral稱,近五分之一的中國人患有心血管疾病。此外,由於可支配收入的增加和人口老化,預計中國和日本等國家的該行業需求將會增加。開發中國家健康旅遊的成長也促進了該領域的產業進步。
According to Stratistics MRC, the Global Drug-eluting Balloon Catheters Market is accounted for $651.0 million in 2023 and is expected to reach $1343.2 million by 2030 growing at a CAGR of 10.9% during the forecast period. Medical devices called drug-eluting balloon catheters (DEBs) are used in interventional cardiology to treat peripheral arterial disease (PAD) and coronary artery disease (CAD). The purpose of these catheters is to administer medication straight to the damaged blood vessel walls in order to stop restenosis, or the constriction of blood vessels after angioplasty treatments. With developments in drug coatings, catheter technology, and continuing clinical research focused on improving patient outcomes and safety, the market for drug-eluting balloon catheters is continually changing.
According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases and growing healthcare spending are projected to bolster market growth
Prevalence of cardiovascular diseases
The number of individuals in need of interventional therapies to control arterial blockages grows in tandem with the frequency of cardiovascular disorders. For these patients, drug-eluting balloon catheters provide an efficient therapeutic alternative that may result in an increase in the number of procedures using these devices. Additionally, healthcare cost is influenced by the financial burden of cardiovascular illnesses, which includes follow-up care, hospital stays, and therapies. Thus drug-eluting balloon catheters are one example of an innovative and successful treatment that may be more widely used if it can be demonstrated to save long-term healthcare expenditures by reducing restenosis and recurring procedures which encourage the growth of the market.
Limited clinical evidence in some lesion types
There may be fewer effective treatment choices available to healthcare practitioners for particular lesion types if there is limited clinical data supporting the use of drug-eluting balloon catheters. This restriction may result in patients with certain arterial lesions not receiving the best care possible, especially if these are thought to be a potentially good alternative but have no solid data to support their use. Even while these systems could be beneficial in some circumstances, they might choose more well-established therapies with more evidence, missing out on chances to improve patient care thereby propel the growth of the market.
Expanding clinical evidence
Drug-eluting balloon catheters are safe, effective, and have good long-term results; this data supports their use and encourages healthcare practitioners to use them. Increased clinical data demonstrating the advantages of drug-eluting balloon catheters can have a favourable impact on healthcare payers' judgments about reimbursement. More proof of better patient outcomes might support reimbursement rules that are more favourable, increasing market access and device usage.
Cost considerations and reimbursement challenges
Patients' access to drug-eluting balloon catheters may be hampered by payment issues, especially in areas or healthcare systems with unfavourable coverage or reimbursement laws. Due to this restriction, patients may not have equal access to cutting-edge therapies, which might have an effect on their prognosis depending on their insurance status or region. Difficulties with reimbursement or hold-ups in receiving positive coverage decisions might hinder drug-eluting balloon catheters market penetration and acceptance.
Covid-19 Impact
Many hospitals and healthcare facilities gave priority to COVID-19 patients when it came to resources during the pandemic's height. Elective operations, including non-urgent cardiac interventions like drug-eluting balloon angioplasty, had to be postponed or cancelled as a result. As a result, the number of procedures performed on the market for these devices decreased. Elective operations and non-urgent interventions showed a steady recovery as vaccination rates rose and healthcare systems adjusted to the epidemic. As a result of several healthcare institutions starting up again, there was an increase in demand for cardiovascular treatments, especially those requiring balloon catheters that release medication.
The coronary artery balloon catheters segment is expected to be the largest during the forecast period
The coronary artery balloon catheters segment is estimated to have a lucrative growth, as these gadgets are intended to unblock or widen coronary arteries in order to replenish blood supply to the heart muscle. In particular, drug-eluting balloon catheters are a kind of catheter that, in order to avoid restenosis, provide medication right to the location of an arterial blockage. Moreover these are becoming more and more popular; as these devices are driven by factors like the need for less invasive procedures, the prevalence of cardiovascular diseases rising, and the fact that drug-eluting balloons reduce restenosis rates more effectively than traditional angioplasty which drives the growth of the market.
The paclitaxel segment is expected to have the highest CAGR during the forecast period
The paclitaxel segment is anticipated to witness the highest CAGR growth during the forecast period, because its usage in drug-eluting balloon (DEB) catheters has drawn a lot of attention and investigation because of worries about its safety, especially in light of possible long-term consequences and a link to higher death rates in patients with peripheral artery disease (PAD). Furthermore, drug-eluting balloon catheters and other paclitaxel-coated goods have seen changes in their market dynamics due to safety concerns surrounding these devices. Thus increased scrutiny, modifications to clinical procedures and conversations about patient selection and long-term safety monitoring have resulted from it.
North America is projected to hold the largest market share during the forecast period owing to the availability of several large manufacturers, the introduction of new, technologically sophisticated equipment, and advantageous reimbursement policies are all key contributors to the market share that is seen in North America. For instance, according to estimates from the American Heart Association, more than 500,000 percutaneous coronary procedures including percutaneous transluminal coronary interventions are performed in the United States each year.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to both the rise in healthcare costs and the prevalence of cardiovascular diseases. According to Biomedcentral, almost one in five Chinese people suffer from cardiovascular disease. Furthermore, it is projected that growing disposable income and an older population in nations like China and Japan would fuel demand in the area. The growth of health tourism in developing nations is also contributing to the industry's progress in this sector.
Key players in the market
Some of the key players profiled in the Drug-eluting Balloon Catheters Market include Aachen Resonance GmbH, B. Braun Melsungen AG, Becton, Dickinson and Company, Biotronik AG, iVascular S.L.U., Lepu Medical Technology (Beijing) Co. Ltd., MedAlliance, Medtronic plc, Biosensors International, Eurocor GmbH, Zhejiang Barty Medical Technology Co.Ltd, Cook Group Incorporated, Terumo Corporation, SurModics Inc, Koninklijke Philips NV, Jotech GmbH, MicroPort Scientific Corporation, Cordis Corporation, Cardionovum GmbH and Abbott Laboratories
In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.
In October 2023, Philips OneBlade Partners with College Rivals for an Epic Gaming Journey Enabling Gen Z to 'Move Fearlessly' this is the third strategic partnership in a year that aims to strengthen the brand's commitment to reaching the GenZ audience.
In August 2023, Philips expands local manufacturing of Personal Health products in India to serve local demand, in addition to the beauty and grooming products already being made at the site.